Amneal receives approval for generic version of ortho evra®

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it has received abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda) for 150 mcg/day norelgestromin and 35 mcg/day ethinyl estradiol transdermal system. in conjunction with its approval, amneal received a competitive generic therapy (cgt) designation by the fda and has been granted 180 days of exclusivity. amneal's norelgestr
AMRX Ratings Summary
Quant
AMRX Quant Ranking
Sector
Industry
Quant Rating
Quant Score